BioPharmSignal logoBioPharmSignal

Biotech News

GENFIT: Favorable Phase 1 Safety Profile and Strong Anti-Inflammatory Activity for ACLF Lead Asset G1090N

GENFIT (GNFT)GENFITClinical readout

Phase 1 results confirm investigational drug-candidate G1090N has a favorable safety and tolerability profile, supporting further clinical evaluation Compelling anti-inflammatory activity of G1090N was evidenced through functional ex vivo assays on blood samples from study participants and

Related news

GNFTGENFIT2026-02-12 17:35 EST

GENFIT to receive US$20M milestone after Ipsen’s Iqirvo® exceeds the US$200M threshold in its first full year of net sales

GNFTGENFIT2026-03-09 17:00 EST

GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF

View all latest news

GENFIT

Liver-Disease Therapeutics and Diagnostics GENFIT develops therapies and diagnostic technologies for liver diseases. Its portfolio combines commercial economics from a partnered product with internal programs in cholangiocarcinoma and acute-on-chronic liver failure. Iqirvo Economics GENFIT receives milestones and royalties from Ipsen’s...

Recent company news

GNFTGENFIT2026-08-03 14:32 EST

GENFIT Answers its Investors – Episode #3 - August 3, 2026

GNFTGENFIT2026-07-08 16:00 EST

Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

GNFTGENFIT2026-07-02 16:05 EST

GENFIT Announces U.S. Medicare Coverage and Future Reimbursement for NASHnext®, a Non-Invasive Diagnostic Technology to Identify Patients with At-Risk MASH

GNFTGENFIT2026-06-23 16:00 EST

GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma

GNFTGENFIT2026-06-15 16:10 EST

GENFIT: June 15, 2026 Combined Shareholders Meeting Results

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States